8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 15, 2026·SEC
Material company update
Mar 23, 2026·SEC
Arbutus Biopharma Corporation(ABUS)Earnings, Financials & Key Ratios
ABUS•NASDAQ
$4.97
Price updated Jul 6, 2026
AboutArbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Show more
- Revenue$14M+128.2%
- EBITDA-$27M+64.4%
- Net Income-$34M+52.1%
- EPS (Diluted)-0.17+55.3%
- Gross Margin97.42%-2.6%
- EBITDA Margin-189.51%+84.4%
- Operating Margin-192.08%+84.5%
- Net Margin-237.88%+79.0%
- ROE-38.52%+44.0%
ABUS Price & Volume
Arbutus Biopharma Corporation (ABUS) stock price & volume — 10-year historical chart
Loading chart...
Nonrecurring Milestone Gains Mask Underlying Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical and litigation outcomes
Key Thesis Takeaways
- Arbutus Biopharma's financial profile is defined by extreme revenue volatility, where a 100.5% growth spike in 2026Q1 obscures a persistent reliance on non-recurring licensing milestones.
- While the company maintains high gross margins, the lack of a self-sustaining operational model is evidenced by a massive accumulated deficit of approximately $1.2B.
- Investors should remain cautious as the firm's R&D-heavy strategy continues to drive significant cash outflows, necessitating potential future dilutive financing to support clinical development.
Verdict Logic
the company's precarious liquidity position, highlighted by a cash balance that dropped to $18.0M in 2025Q4, suggests significant risk for long-term shareholders.
ABUS Growth Metrics
Arbutus Biopharma Corporation (ABUS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-5.53%
5 Years15.29%
3 Years-28.8%
TTM2889.93%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM309.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM302.11%
Return on Capital
10 Years-55.85%
5 Years-45.62%
3 Years-48.49%
Last Year-26.43%
ABUS Recent Earnings
Arbutus Biopharma Corporation (ABUS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.87+3000.0%
$0.03
Rev
$179M+23783.5%
$750,000
Q2 2026
Mar 23, 2026Metric
Actual
Est
EPS
$0.01+71.5%
$0.04
Rev
$1M+71.0%
$614,500
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.04+28.6%
$0.06
Rev
$529,000-37.1%
$841,000
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.01+150.0%
$0.02
Rev
$11M+575.0%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.87vs $0.03+3000.0% | $179Mvs $750,000+23783.5% |
| Q2 2026 | Mar 23, 2026 | $0.01vs $0.04+71.5% | $1Mvs $614,500+71.0% |
| Q4 2025 | Nov 13, 2025 | $0.04vs $0.06+28.6% | $529,000vs $841,000-37.1% |
| Q3 2025 | Aug 6, 2025 | $0.01vs $0.02+150.0% | $11Mvs $2M+575.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Arbutus Biopharma Corporation (ABUS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.97 | $981.76M | -29.24 | 128.21% | -237.88% | -38.52% | — | |
| $11.47 | $962.85M | -3.39 | — | — | -128.57% | — | |
| $28.90 | $459.22M | -52.54 | 153.52% | -8.98% | -4.21% | — | |
| $6.35 | $28.64M | -0.50 | -8.06% | -11.44% | -73.04% | — | |
| $38.71 | $4.49B | -12.13 | — | — | -71.31% | — | |
| $129.61 | $160.92B | 19.12 | 2.39% | 30.99% | 42.33% | — |
Compare ABUS vs Peers
Arbutus Biopharma Corporation (ABUS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ABUS SEC Filings & Documents
Arbutus Biopharma Corporation (ABUS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ABUS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ABUS Frequently Asked Questions
Arbutus Biopharma Corporation (ABUS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Arbutus Biopharma Corporation's revenue?
Arbutus Biopharma Corporation (ABUS) reported $191.4M in revenue for fiscal year 2025. This represents a 15498% increase from $1.2M in 1998.
How fast is Arbutus Biopharma Corporation growing?
Arbutus Biopharma Corporation (ABUS) grew revenue by 128.2% over the past year. This is strong growth.
Is ABUS profitable?
Yes, Arbutus Biopharma Corporation (ABUS) is profitable, generating $160.7M in net income for fiscal year 2025 (-237.9% net margin).
Dividend & Returns
What is ABUS's return on equity?
Arbutus Biopharma Corporation (ABUS) has a return on equity (ROE) of -38.5%. Negative ROE indicates the company is unprofitable.
What is Arbutus Biopharma Corporation's free cash flow?
Arbutus Biopharma Corporation (ABUS) had negative free cash flow of $34.4M in fiscal year 2025, likely due to heavy capital investments.